Pembrolizumab-Sacituzumab Govitecan Combination to Treat High-risk, Localized Bladder Cancer
Pembrolizumab-Sacituzumab Govitecan Combination to Treat High-risk, Localized Bladder Cancer
Active, not recruiting · NCT05535218 · Registry updated 2025-04-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pembrolizumab-Sacituzumab Govitecan Combination to Treat High-risk, Localized Bladder Cancer | Muscle-invasive Urothelial Carcinoma of the Bladder | Active, not recruiting | Phase 2 | 2025-04-02 | NCT05535218 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Claudia Guerrieri | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Fondazione San Raffaele | Milan | Italy | 1 |